1. An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials
Obes Facts 2012;5:485– DOI: /
Fig. 1. Occurrence of two successive abnormal ALT measurements (60 and 120 mg orlistat combined).
© 2012 S. Karger AG, Basel

2. An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials
Obes Facts 2012;5:485– DOI: /
Fig. 2. Occurrence of two successive abnormal bilirubin measurements (60 and 120 mg orlistat combined).
© 2012 S. Karger AG, Basel

3. An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials
Obes Facts 2012;5:485– DOI: /
Fig. 3. mDISH plot between orlistat (60 and 120 mg combined) and placebo.
© 2012 S. Karger AG, Basel

4. An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials
Obes Facts 2012;5:485– DOI: /
Fig. 4. A subject showing high ALT and bilirubin.
© 2012 S. Karger AG, Basel

5. An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials
Obes Facts 2012;5:485– DOI: /
Fig. 5. K-M estimates of difference in treatment-emergent LFT signals between orlistat (60 and 120 mg combined) and placebo. Note: Vertical line represents error bar (± standard error).
© 2012 S. Karger AG, Basel